Utilizing Multi-Agent Reinforcement Learning with Encoder-Decoder Architecture Agents to Identify Optimal Resection Location in Glioblastoma Multiforme Patients

Summary

This research presents an end-to-end AI system designed to assist doctors with both the diagnosis and treatment planning of Glioblastoma Multiforme (GBM), the deadliest human cancer. Utilizing a sequential decision-making framework for diagnosis and a Multi-Agent Reinforcement Learning (MARL) system with generative encoder-decoder architecture agents for treatment planning, the project significantly reduces computational costs and tumor progression inference time while improving segmentation accuracy, projecting to increase GBM survival rates.

Medical Relevance

This system addresses a critical unmet need in treating Glioblastoma Multiforme, the deadliest human cancer, by providing an AI-driven, end-to-end diagnostic and personalized treatment planning solution. By improving the identification of optimal resection locations and simulating treatment outcomes, it aims to directly impact patient survival rates and standardize complex decision-making in neuro-oncology.

AI Health Application

The AI system provides an end-to-end solution for Glioblastoma Multiforme management. It assists with medical diagnosis using a sequential decision-making framework, and for treatment planning, it leverages generative AI models (diffusion models, vision transformers) to predict outcomes of various interventions (resection, radiotherapy, chemotherapy) and iteratively optimize the resection location based on a predicted survival rate. This directly supports clinical decision-making and aims to improve patient outcomes in brain cancer.

Key Points

• The system provides an end-to-end AI solution for Glioblastoma Multiforme (GBM), covering both diagnostic classification and personalized treatment planning.
• Diagnosis employs a sequential decision-making framework with four progressive classification models (Convolutional Neural Networks and Support Vector Machines) to classify brain regions into increasingly specific categories.
• Treatment planning utilizes a Multi-Agent Reinforcement Learning (MARL) system comprising three generative models: a Diffusion Model for resection prediction, a Spatio-Temporal Vision Transformer for radiotherapy progression simulation, and another Diffusion Model for chemotherapy outcomes.
• A feedback loop driven by Proximal Policy Optimization (PPO) iteratively refines the proposed treatment plan, specifically identifying optimal resection locations, based on a CNN-powered survival rate calculator's assessment against a user-defined target.
• The sequential diagnostic framework achieved a 22.28x reduction in computing costs compared to existing solutions.
• The Spatio-Temporal Vision Transformer for radiotherapy progression decreased tumor progression inference time by 113 hours.
• Incorporating real-life resembling augmentations during training improved overall DICE scores (segmentation accuracy) by 2.9%.
• The project projects a potential 0.9% increase in GBM survival rates, translating to approximately 2,250 lives saved annually.

Clinical Impact

This AI system has the potential to significantly impact GBM patient care by offering more precise and personalized diagnosis and treatment planning. The reduced computational burden and faster inference times can enable quicker clinical decisions. The improved accuracy in identifying optimal resection locations and predicting treatment outcomes could lead to higher surgical efficacy, better treatment tailoring, and ultimately, an estimated increase in patient survival rates by nearly 1%, potentially saving thousands of lives annually.

Limitations

The abstract does not explicitly state specific limitations of the developed system or the study itself. However, as an abstract, it presents high-level results, and detailed limitations would typically be discussed in the full paper.

Future Directions

The abstract does not explicitly state future research directions. However, given the nature of the findings, potential future work could involve clinical validation, integration into hospital systems, expansion to other brain tumor types, and real-world evaluation of the projected survival rate improvements.

Medical Domains

Keywords

Abstract

Currently, there is a noticeable lack of AI in the medical field to support doctors in treating heterogenous brain tumors such as Glioblastoma Multiforme (GBM), the deadliest human cancer in the world with a five-year survival rate of just 5.1%. This project develops an AI system offering the only end-to-end solution by aiding doctors with both diagnosis and treatment planning. In the diagnosis phase, a sequential decision-making framework consisting of 4 classification models (Convolutional Neural Networks and Support Vector Machine) are used. Each model progressively classifies the patient's brain into increasingly specific categories, with the final step being named diagnosis. For treatment planning, an RL system consisting of 3 generative models is used. First, the resection model (diffusion model) analyzes the diagnosed GBM MRI and predicts a possible resection outcome. Second, the radiotherapy model (Spatio-Temporal Vision Transformer) generates an MRI of the brain's progression after a user-defined number of weeks. Third, the chemotherapy model (Diffusion Model) produces the post-treatment MRI. A survival rate calculator (Convolutional Neural Network) then checks if the generated post treatment MRI has a survival rate within 15% of the user defined target. If not, a feedback loop using proximal policy optimization iterates over this system until an optimal resection location is identified. When compared to existing solutions, this project found 3 key findings: (1) Using a sequential decision-making framework consisting of 4 small diagnostic models reduced computing costs by 22.28x, (2) Transformers regression capabilities decreased tumor progression inference time by 113 hours, and (3) Applying Augmentations resembling Real-life situations improved overall DICE scores by 2.9%. These results project to increase survival rates by 0.9%, potentially saving approximately 2,250 lives.